Overview DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Status: RECRUITING Trial end date: 2030-06-30 Target enrollment: Participant gender: Summary A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid TumorsPhase: PHASE2 Details Lead Sponsor: DualityBio Inc.Collaborator: BioNTech SE